menu
    • menu
    [{"orgOrder":0,"company":"Sheba Medical Center","sponsor":"Race Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bisantrene","moa":"DNA | Alpha-ketoglutarate-dependent dioxygenase FTO","graph1":"Oncology","graph2":"Phase II","graph3":"Sheba Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sheba Medical Center \/ Race Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Sheba Medical Center \/ Race Oncology"},{"orgOrder":0,"company":"Sheba Medical Center","sponsor":"Race Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bisantrene","moa":"DNA | Alpha-ketoglutarate-dependent dioxygenase FTO","graph1":"Oncology","graph2":"Phase II","graph3":"Sheba Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sheba Medical Center \/ Race Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Sheba Medical Center \/ Race Oncology"},{"orgOrder":0,"company":"City of Hope","sponsor":"Race Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Bisantrene","moa":"DNA | Alpha-ketoglutarate-dependent dioxygenase FTO","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Race Oncology","highestDevelopmentStatusID":"9","companyTruncated":"City of Hope \/ Race Oncology"},{"orgOrder":0,"company":"Ardena","sponsor":"Race Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Bisantrene","moa":"FTO protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Ardena","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ardena \/ Race Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Ardena \/ Race Oncology"},{"orgOrder":0,"company":"Race Oncology","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bisantrene","moa":"FTO protein","graph1":"Oncology","graph2":"Phase I","graph3":"Race Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Race Oncology \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Race Oncology \/ Astex Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Bisantrene

    Menu

    Bisantrene

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ardena

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardena

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bisantrene,Bisantrene DiHCl

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Race Oncology

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ardena Signs Agreement with Race Oncology Limited to Manufacture RC220

                            Details : Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 12, 2023

                            Lead Product(s) : Bisantrene,Bisantrene DiHCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Race Oncology

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            City of Hope

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            City of Hope

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bisantrene

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Race Oncology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Race Executes Global License Agreement with City of Hope to Access FTO IP

                            Details : Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene may be the most potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 10, 2023

                            Lead Product(s) : Bisantrene

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Race Oncology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Race Oncology

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Race Oncology

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bisantrene

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Astex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML a...

                            Details : Bisantrene Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 13, 2022

                            Lead Product(s) : Bisantrene

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Astex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sheba Medical Center

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sheba Medical Center

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bisantrene

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Race Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bisantrene Combination for Resistant AML

                            Details : Bisantrene is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 04, 2021

                            Lead Product(s) : Bisantrene

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Race Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sheba Medical Center

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sheba Medical Center

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bisantrene

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Race Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bisantrene for Relapsed /Refractory AML

                            Details : Bisantrene is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 29, 2019

                            Lead Product(s) : Bisantrene

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Race Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth